<DOC>
	<DOCNO>NCT01391520</DOCNO>
	<brief_summary>This trial evaluate whether treatment CRMD001 ( unique formulation iron chelator , Deferiprone ) reduce morbidity mortality subject Chronic Kidney Disease ( CKD ) additional risk factor . Adult subject moderate severe CKD undergoing diagnostic interventional coronary angiography randomize either placebo CRMD001 follow 90 day . Subjects receive 8 day randomize therapy start 1-3 hour prior angiography . The primary endpoint trial difference composite specify renal cardiovascular clinical event occur Day 90 .</brief_summary>
	<brief_title>Efficacy Safety Deferiprone Patients With Chronic Kidney Disease Undergoing Cardiac Catheterization Receiving Contrast Agent</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>1 . Age 18 old 2. eGFR 15 ml/min/1.73 m2 &lt; 60 ml/min/1.73 m2 3 . Presence least one additional risk factor : Diabetes Mellitus type 1 2 Age ≥ 75 year Left Ventricular Ejection Fraction ≤ 40 % 1 . EndStage Renal Disease 2 . Primary PCI STEMI 3 . Currently receive mechanical ventilation 4 . Known active liver disease liver failure 5 . Evidence hemodynamic instability , requirement pressor agent 6 . Exposure contrast medium within prior 10 day 7 . Currently receive fenoldopam , dopamine , theophylline , aminophylline , mannitol , Ascorbic acid ( &gt; 2 g/day ) 8 . Absolute neutrophil count &lt; 1500</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Acute Kidney Injury</keyword>
	<keyword>Contrast-Induced Nephropathy</keyword>
	<keyword>Labile Iron</keyword>
	<keyword>Iron Chelation</keyword>
	<keyword>Deferiprone</keyword>
</DOC>